MERCK KGAA, TAKEDA TO DEVELOP MATUZUMAB CANCER DRUG

Merck KGaA, which sells the Erbitux tumor treatment in Europe, will get a 60-million-euro ($72.4 million) payment from Takeda Pharmaceutical Co. as the companies develop an experimental medicine for several types of cancer. Takeda, Japan's largest drugmaker, will make additional significant'' payments to Merck as certain goals are achieved, Darmstadt, Germany-based Merck said today in an e-mailed statement.

Bloomberg (http://www.bloomberg.com/apps/news?pid=10000101&sid=amFMBoGbD67Y&refer=japan)